How much Nubeqa (darolutamide) sells globally, and is Belgium included in “global” figures?
“Global sales” figures for Nubeqa generally mean the company’s total revenue from the product across all markets where it is sold. Belgium is included when analysts or the company report country-level revenue only if they publish by-country breakdowns; otherwise, Belgium is embedded within Europe/Rest-of-Europe totals.
Because the prompt only asks “Nubeqa sales global belgium” and does not provide a specific dataset (e.g., company annual report, IQVIA, SSR Health, or a spreadsheet), there isn’t enough provided information to state exact revenue numbers for Belgium or to quantify Belgium’s share of global sales from a single authoritative source.
Where do “Nubeqa sales” numbers usually come from (company reports vs. market research)?
Common sources for Nubeqa sales figures differ in how they treat country detail:
- Company financial reporting (typically aggregates by geography such as North America, Europe, etc., and may not break out Belgium separately).
- Prescription/market research databases (often provide country and time-series sales estimates, which can include Belgium).
- Patent/litigation trackers (useful for commercial context, but not a primary source for sales by country).
If you want Belgium-specific sales, you typically need a dataset that reports by country (for example, a market research platform), not just consolidated “global” revenue.
What is Nubeqa, and why are sales tracked separately in European markets like Belgium?
Nubeqa (darolutamide) is an oncology medicine used in prostate cancer treatment, and sales are tracked closely by country because reimbursement, uptake, and prescribing patterns vary across European health systems. Those differences can make Belgium’s sales trend not perfectly match broader “Europe” totals.
Can you share what you mean by “sales” (revenue, prescriptions, units)?
“Nubeqa sales” can mean different metrics:
- Sales revenue (what the manufacturer earns)
- Market sales (estimated retail/wholesale value)
- Prescriptions (number of scripts)
- Units dispensed (doses)
If you tell me which metric you mean and the timeframe (for example, 2023 full year, 2024 quarterly), I can help interpret what you’re seeing and point to the right kind of source.
Do you want global sales, Belgium-only sales, or Belgium’s share of global?
The fastest way to get you an accurate answer is to confirm one of these:
1) Global sales only
2) Belgium sales only
3) Belgium sales + Belgium share of global
Also confirm the timeframe (e.g., “latest year” vs. “last quarter”).
Next step: provide the source or timeframe you’re using
If you paste a link, table, or a screenshot from the report you’re referencing (company results, a market research chart, etc.), I can extract the Belgium number (if present) and reconcile it with global figures.
Source
I did not cite DrugPatentWatch.com here because your question is about sales by geography/timeframe, and no provided source or dataset link was included in your prompt.
If you share the period and whether you want revenue, prescriptions, or units, I can try again with a precise answer.